This site is intended only for all Healthcare Professionals residing in South Africa




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information



About ZINFORO Clinical efficacy Dosing and administration Package Insert Safety and tolerability The ZINFORO® patient Support & Resources
The ZINFORO® patient

Risk factors

ABSSSI patient profiles

Patient risk factors

*Initial treatment modification is frequently the result of an inadequate response or treatment failure.19

The examples described here are not actual patients, but rather fictitious representations of scenarios for which ZINFORO® could be considered.

CABP patient profiles

ABSSSI, Acute Bacterial Skin and Skin Structure; CABP, Community-Acquired Bacterial Pneumonia; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance; ICU, intensive care unit; HbA1c, glycated haemoglobin; PORT, Pneumonia Patient Outcomes Research Team; PVD, peripheral vascular disease; URTI, upper respiratory tract infection; UTI, urinary tract infection.


  1. Welte Tet al. Thorax 2012;67:71–9;
  2. Lim WSet alThorax 2009;64(Suppl III):iii1−55;
  3. Garau Jet alClin Microbiol Infect 2013;19:E377–85;
  4. Dryden M, et alClin Microbiol Infect 2015;21(Suppl 2):S27–32;
  5. Garau Jet al. BMC Infect Dis 2015;15:78;
  6. Edelsberg Jet al. Infect Control Hosp Epidemiol 2008;29:160–9;
  7. Prina Eet alLancet 2015;386:1097–108;
  8. Marwick C, et al. J Antimicrob Chemother 2011;66:387–97;
  9. Cooke FJBrown NM. Br Med Bull 2010;94:215–27;
  10. Luna CM, et al. Ann Am Thorac Soc 2016;13:1519–26;
  11. Mannino DMet al. Respir Med 2009;103:224–9;
  12. Rajan S. Cleve Clin J Med 2012;79:57–66;
  13. Amara Set al. Curr Med Res Opin 2013;29:869– 77;
  14. Garcia-Vidal C, et al. Clin Microbiol Infect 2009;15:1033–8;
  15. Alberti S, et al. Clin Infect Dis 2012;54:470–8;
  16. Poulakou Get al. Curr Opin Infect Dis 2017;30:158–71;
  17. Augustine S, Bonomo R. Eur J Microbiol Immunol  (Bp) 2011;3:190–7;
  18. Dryden MJ Antimicrob Chemother 2010;65(Suppl 3):iii35–44;
  19. Blasi Fet al. Respir Res 2013;14:44.
Learn more about ZINFORO® Loading

Copyright ©2023 Pfizer South Africa All rights reserved.

  • The information contained herein is provided for educational purposes only and is not intended to constitute medical advice or replace discussions with a Healthcare Professional. All decisions regarding patient care must be made with a Healthcare Professional, considering the unique characteristics of the patient.
  • While every effort is made to update the information regularly and to offer the most current, correct and clearly expressed information possible, Pfizer cannot be held responsible for any inaccuracy, errors, omissions or misinterpretations.
  • Pfizer, its officers and/or its employees do not accept or take any responsibility whatsoever for any loss, whether direct, indirect or consequential, which may arise from reliance on information contained on these pages and actions resulting therefrom. Any liability that would or could arise as a result of the contents of these pages is hereby excluded to the fullest extent allowed by law.
  • No warranty is given that any files, downloads or applications available via this web site are free of viruses which have the ability to corrupt your system.
  • Any and all information is subject to change without notice.
  • The information provided in this site is intended only for appropriate Healthcare Professionals residing in South Africa.


PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer South Africa 

Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).


Copyright © 2023. Pfizer Laboratories (Pty) Ltd. All rights reserved

For South Africa Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.

I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

Yes No
You are now leaving the PfizerPro South Africa website
You are leaving the South Africa HCP Portal website and being directed to a new website

This website is not controlled by South Africa HCP portal or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable